Salute e Benessere

Nexstim Plc: Proposals of the Shareholder's Nomination Board to the Annual…

Company announcement, Helsinki, 31 January 2024 at 10 AM (EET)Nexstim Plc: Proposals of the Shareholder's Nomination Board to the Annual General Meeting The Shareholder's Nomination Board of Nexstim Corporation (NXTMH:HEX) (“Nexstim” or the “Company”) has on 30 January 2024 in its meeting resolved its proposal to the Annual General Meeting of Nexstim, which will be held on Thursday March 28, 2024.The Nomination Board of Shareholders representing the largest shareholders proposes to...

Biosurfactants Market to Reach $3.2 Billion, Globally, by 2032 at 5.4% CAGR…

Prime determinants of growth Prime determinants of growth The global biosurfactants market is driven by robust demand from pharmaceutical sector. The rapid increase in population, rise in pharmaceuticals R&D, up-gradation in technology, increase in focus in the healthcare field in developed & developing nations such as the U.S.,China, andIndia, and rise in the incidence rate of chronic disorder have surged the demand for biosurfactants in the pharmaceutical sector...

SKF Year-end report 2023: Strategy execution yielding strong performance

Net sales: SEK 24,438 million (25,361) Organic growth: -1.9% (9.7%) Adjusted operating profit/margin: SEK 2,929 million, 12.0% (2,542, 10.0%) Net sales: SEK 24,438 million(25,361)Organic growth:-1.9% (9.7%)Adjusted operating profit/margin: SEK 2,929 million, 12.0% (2,542, 10.0%) Full year 2023 Net sales: SEK 103,881 million(96,933)Organic growth:3.7% (8.1%)Adjusted operating profit/margin :SEK 12,977 million, 12.5% (10,204, 10.5%) Rickard Gustafson,...

LifeArc makes multi-million pound investment to support drug discovery in…

LifeArc makes multi-million pound investment to support drug discovery in sub-Saharan Africa LifeArc and the Bill & Melinda Gates Foundation are jointly investing £6 million ($7.2m) to enhance drug discovery capabilities in sub-Saharan Africa. Funding aims to support drug discovery projects led by African scientists including a potential treatment for malaria and a new approach to target tuberculosis. The programme also addresses challenges in global research equity and seeks...

AWARD WINNING BEAUTY BRAND TARAMAR INSPIRED BY ICELAND'S NATURE SECRETS

Enabled by their patented NoTox technology, TARAMAR's commitment to harnessing the power of Iceland's unique environment in a safe and pure way, sets them apart from other skincare brands. By combining scientific expertise with nature's gifts, they have created a range of products that not only enhance skin health but also provide a luxurious and indulgent experience. Enabled by their patented NoTox technology, TARAMAR's commitment to harnessing the power ofIceland'sunique environment in a...

Sobi to present new data at EAHAD 2024

Key Sobi data to be presented at EAHAD 2024 Key Sobi data to be presented at EAHAD 2024 All presentations can be accessed via the official EAHAD 2024 website. About efanesoctocog alfa Efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is a new class and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for a significant parts of the week, improving bleed...

Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant…

Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023 Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 Operating profit increased by 37% in Danish kroner and by 44% at constant exchange rates...

Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for…

Press ReleaseNicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA ®January 31, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has determined that U.S. Patent No. 7,629,345, which covers latanoprostene bunod, commercialized by...

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright &…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024– Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) with respect to an at-the-market offering program under which the Company may offer and sell, from...

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko®…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko ®approved for all indications of reference medicine Tyruko ®biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS) Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024– Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko ®...

Novartis delivers strong full year performance, 10% net sales and 18% core…

Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations 2 )Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD) Sales growth was mainly driven by continued strong performance fromEntresto(+31% cc),Kesimpta(+99% cc),Kisqali(+75% cc),Pluvicto(+261% cc) andScemblix(+179% cc) Operating income increased +39% (cc, +23% USD).Net income increased +62% (cc, +42% USD). Free cash flow from…

Geneva Court Grants Temporary Moratorium to ObsEva

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium ( sursis provisoire ) by the competent court in Geneva, Switzerland. TheTribunal de première instanceof Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner...

IBA – TRANSPARENCY NOTIFICATION

(Article 14, paragr aph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, January 31, 2024 01:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification...

Industry leader, Colonel Andre Cap, U.S. Army, retired, joins Velico As Chief…

He has worked extensively with the Armed Services Blood Program, Special Operations Command and Joint Trauma System (JTS) on a variety of blood and combat casualty care challenges. He served as Co-Chairman of the NATO Blood Panel and as a contributor to the NATO Prehospital Care Improvement Initiative. He has worked extensively with the Armed Services Blood Program, Special Operations Command and Joint Trauma System ( JTS ) on a variety of blood and combat casualty care challenges. He served...

The Prebiotics Market to Hit $13.26 Billion by 2029, Fructo-oligo-Saccharides…

The Global Prebiotics Market Report Scope The Global Prebiotics Market Report Scope The growing awareness of the health benefits of prebiotics, such as improved gut health and overall digestive function, and increased consumption of functional dairy products is anticipated to boost the growth of the global market. APAC has the largest share in 2023 and is the fastest-growing probiotics market from 2023 to 2029. The constant development and launch of innovative products are...

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of US and is also seeing increasing traction in ROW...

Robust Growth in Autonomous Mobile Robots Market - the Market to Hit $23.69…

To Know More, Download the Free Sample Report: https://www.arizton.com/request-sample/4084 To Know More, Download the Free Sample Report:https://www.arizton.com/request-sample/4084 Browse in-depth TOC on the Autonomous Mobile Robots Market 311 – Pages 79 - Tables 96 - Figures Autonomous Mobile Robots Market Report Scope • Labor Shortage & Cost Reduction • Increasing Automation in Material Handling E-Commerce Expansion Creating...

Venous Stents Market to Reach $2,809.7 Million by 2030, Growing at a Robust…

Get a Sample Copy of the Report: https://www.kingsresearch.com/request-sample/venous-stents-market-125 Get a Sample Copy of the Report: https://www.kingsresearch.com/request-sample/venous-stents-market-125 Trending Now: Inari Medical Introduces Two Novel Thrombectomy Catheters InJune 2023, Inari Medical, a medical device company, introduced two newly designed thrombectomy catheters specifically tailored to address the challenges associated with venous stent thrombosis and...

Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP

FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUPContinued total year growth in core business revenues, up 39%Successful deployment of the Group's strategy: Proprietary products up at 30% of revenuesInternationalization, with 38% of revenues now generated outside of FranceAcquisition of DID in Italy effective as of July 1 st, 2023Acquisition of Alpha Biotech, GenDx distributor, effective as of January 3 rd, 2024Paris, January 30, 2024 – 5:45 pmEurobio...

Theranostics Market Worth $4.3 Billion | MarketsandMarkets™

Browse in-depth TOC on "Theranostics Market" Browse in-depth TOC on "Theranostics Market" 94 - Tables 40 - Figures 196 - Pages Theranostics Market Scope: Radiopharmaceuticals segment to register significant growth rate over the forecast period of 2023-2028. Based on the product, the global theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/Biomarker screening, and software and services. The radiopharmaceuticals segment is anticipated to...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 30 January 2024– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…

FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with…

MINNEAPOLIS and CARMARTHENSHIRE, United Kingdom, Jan.30, 2024(GLOBE NEWSWIRE) -- Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon 3.0 with StimGuide Pro. This provides physicians, nurse practitioners, clinicians, and researchers with the most advanced transcranial magnetic stimulation technology (TMS) available to treat patients diagnosed with depressive or obsessive-compulsive conditions*. “With just one...

Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman

Huxley Health Inc.(“ Huxley ” or the “ Company ”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year. Key Highlights:Acquisition of Sintalica Corp:Huxley strengthens its position in psychedelics-based treatments for Neuroinflammatory Disorders through the successful acquisition of Sintalica Corp. New Leadership:High profile additions creating a dynamic,...

Metacon publishes prospectus in connection with the rights issue

Publication of the Prospectus Publication of the Prospectus Complete information regarding the Rights Issue is included in the Prospectus that has been prepared by the Company and which today was approved and registered by the Swedish Financial Supervisory Authority. The Prospectus has been prepared as a simplified prospectus for secondary issuances in accordance with Article 14 of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The SFSA, as the Swedish national competent...

Altri Comunicati